cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mirati Therapeutics Inc
2 own
11 watching
Current Price
$50.52
$-3.19
(-5.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,908.37M
52-Week High
52-Week High
114.745
52-Week Low
52-Week Low
32.96
Average Volume
Average Volume
0.91M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,908.37M
icon52-Week High114.745
icon52-Week Low32.96
iconAverage Volume0.91M
iconDividend Yield--
iconP/E Ratio--
What does the Mirati Therapeutics Inc do?
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Read More
How much money does Mirati Therapeutics Inc make?
News & Events about Mirati Therapeutics Inc.
Ticker Report
12days ago
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Rating) have earned an average recommendation of Hold from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ...
Zolmax
1month ago
Mirati Therapeutics (NASDAQ:MRTX Get Rating) had its price target cut by Barclays from $169.00 to $90.00 in a research report released on Wednesday, The Fly reports. Several other research firms also recently weighed in on MRTX. B. Riley began coverage on Mirati Therapeutics in a report on ...
PR Newswire
2 months ago
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study PR Newswire SAN DIEGO, Dec. 2, 2022 Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer...
Zolmax
2 months ago
Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Rating) insider Charles M. Baum sold 69,256 shares of the companys stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $100.00, for a total transaction of $6,925,600.00. Following the completion of the ...
PR Newswire
2 months ago
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO PR Newswire SAN DIEGO, Nov. 28, 2022 SAN DIEGO, Nov. 28, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Mirati Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Mirati Therapeutics Inc shares?
plus_minus_icon
How can I buy Mirati Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Mirati Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mirati Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Mirati Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Mirati Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mirati Therapeutics Inc?
plus_minus_icon
What percentage is Mirati Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mirati Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$50.52
$-3.19
(-5.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Revance Therapeutics Inc
Revance Therapeutics Inc
$33.16
$-1.48 (-4.29 %)
FibroGen Inc
FibroGen Inc
$24.48
$-0.70 (-2.78 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$44.07
$-1.78 (-3.88 %)
Galapagos NV
Galapagos NV
$43.58
$0.18 (0.41 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Revance Therapeutics Inc
Revance Therapeutics Inc
$33.16
$-1.48 (-4.29 %)
FibroGen Inc
FibroGen Inc
$24.48
$-0.70 (-2.78 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$44.07
$-1.78 (-3.88 %)
Galapagos NV
Galapagos NV
$43.58
$0.18 (0.41 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00